Senores to acquire Apnar Pharma with USFDA plant for about Rs 91 crore

Promoter Disclosed Acquisition PlansMgmt Guided Margin ImprovementInvestor Communications View source PDF Explain this filing

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.5%Reaction day

₹817.00

prior close

₹825.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.6%+1.1% vs market

Pharmaceuticals peers, median of 159sector-0.4%+0.9% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-1.2

15m

-1.6

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.5-0.6+1.1-0.4+0.9

Next day

-2.2-1.5-0.7-1.2-1.0

-2.0-1.8-0.1-1.3-0.7

-1.9-0.6-1.3-0.4-1.5

+0.4+0.8-0.4+0.1+0.3

-1.5+0.8-2.3+0.3-1.7

-0.7-0.2-0.5-0.6-0.2

15d

+5.5+1.1+4.5+0.9+4.6

-3.7-3.5-0.1-2.5-1.2

-3.2-3.2+0.1-4.3+1.1

-8.3-12.8+4.4-11.5+3.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Senores will acquire 100 percent of Apnar Pharma, which operates a USFDA approved manufacturing plant in Gujarat. Total deal value is about Rs 91 crore, covering Rs 76 crore debt and Rs 15 crore cash paid in two tranches by March 2026 and Q2 FY2027. Senores is also buying 5 ANDAs, of which 3 are validated, with a 722 million dollar market opportunity. Funding will come from IPO proceeds and internal accruals. Management expects margin expansion, better operating leverage, and entry into UK and Canada markets.

Likely market impact

Deal adds USFDA capacity, 5 ANDAs with about 722 million dollar market scope, and entry into UK and Canada. Positive for long term growth.